ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.064
Abstract: Approximately 50% of nGBMs harbor EGFR-amp. Depatuxizumab mafodotin (depatux-m) is an antibody drug conjugate: a monoclonal antibody that binds activated EGFR (wild-type and EGFRvIII mutant) linked to a microtubule-inhibitor toxin. Pre-clinical and earlier clinical trials… read more here.
Keywords: placebo; egfr; trial; depatuxizumab mafodotin ... See more keywords
Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate: [RETRACTED].
Sign Up to like & getrecommendations! Published in 2018 at "Cornea"
DOI: 10.1097/ico.0000000000001635
Abstract: PURPOSE To report the first histological characterization of microcyst-like epithelial keratopathy (MEK) associated with depatuxizumab mafodotin (ABT-414). METHODS Case report. RESULTS A 35-year-old man with glioblastoma multiforme participating in a phase III trial of the… read more here.
Keywords: depatuxizumab mafodotin; mafodotin abt; histological characterization; abt 414 ... See more keywords
A Phase 3b Study for Management of Ocular Side Effects in Patients with EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.
Sign Up to like & getrecommendations! Published in 2023 at "Ophthalmic research"
DOI: 10.1159/000531142
Abstract: INTRODUCTION The Understanding New Interventions with GBM ThErapy (UNITE) study was designed to assess the effect of prophylaxis for ocular side effects (OSEs) in patients with glioblastoma receiving the antibody-drug conjugate (ADC) depatuxizumab mafodotin. UNITE… read more here.
Keywords: eye; study; depatuxizumab mafodotin; phase ... See more keywords